Skip to main content
Article thumbnail
Location of Repository

Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities

By Jane A. Pinaire, Anne Reifel Miller and Francine M. Gregoire
Topics: Editorial
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2659606
Provided by: PubMed Central

Suggested articles

Citations

  1. (2007). A .R u b e n s t r u n k ,R .H a n f
  2. (2006). C.Fi´ evet,J.-C.Fruchart,andB.Staels,“PPARαandPPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome,” Current Opinion
  3. (2007). Effect of rosiglitazone on the risk ofmyocardialinfarctionanddeathfromcardiovascularcauses,” TheNewEnglandJournalofMedicine,vol.356,no.24,pp.2457– 2471,
  4. (1990). I.IssemannandS.Green,“ A ctivationofamemberofthesteroid hormone receptor superfamily by peroxisome proliferators,”
  5. (2007). Nonclinical safety evaluation of muraglitazar, a novel PPARα/γ agonist,”
  6. (2007). PPAR dual agonists: are they opening
  7. (2007). The next generation of PPAR drugs: do we have the tools to find them?”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.